Lorianne Masuoka
Equibles does not estimate personal net worth.
About Lorianne Masuoka
DiaMedica Therapeutics Inc. reported in an 8-K filed August 6, 2025 that Lorianne Masuoka resigned as Chief Medical Officer, effective August 4, 2025. The proxy statement of DiaMedica Therapeutics Inc. reports total compensation of $1,174,310 for Lorianne Masuoka in fiscal 2024, including a base salary of $403,277. Lorianne Masuoka has spoken on 2 earnings calls across 1 company, most recently for DiaMedica Therapeutics Inc. on March 17, 2025. The companies whose calls Lorianne Masuoka spoke on are classified in the Healthcare sector.
“Effective August 4, 2025, Lorianne Masuoka, M.D. resigned as Chief Medical Officer of DiaMedica Therapeutics Inc. (the "Company"), effective as of August 4, 2025, for personal reasons.”
Lorianne Masuoka on recent calls
“Starting with preeclampsia, we are very pleased with our progress in this clinical program. Less than a year ago, our collaborators submitted the first draft of the protocol to the Tygerberg Hospital's Ethics Board.”
“I'm pleased with our recent announcement that we have dosed the first participant since the restart of our ReMEDy2 trial. Enrolling the first participant is particularly challenging and a crucial milestone when coming off the clinical hold for a safety event.”
Affiliation history
-
DiaMedica Therapeutics Inc. (DMAC)
Source not stated
Start not stated–2025-08-04
Company network
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | DiaMedica Therapeutics Inc. (DMAC) | Chief Medical Officer | $403,277 | $1,174,310 |